Key result
Perioperative dexmedetomidine fails to reduce post-operative AKI risk versus placebo in non-cardiac surgery.
Why the study?
Post-operative acute kidney injury is a common and serious complication after major surgery, prompting an evaluation of the effects of perioperative dexmedetomidine on AKI and recovery outcomes after non-cardiac surgery.
Does perioperative dexmedetomidine administration reduce the occurrence of post-operative acute kidney injury in patients undergoing non-cardiac surgery?
Comparison
Perioperative dexmedetomidine vs placebo
Authors
Loading...
No AKI risk reduction with perioperative dexmedetomidine after non-cardiac surgery; challenges observational signals and leaves efficacy open for larger RCTs.
Does perioperative dexmedetomidine administration reduce the occurrence of post-operative acute kidney injury in patients undergoing non-cardiac surgery?
Perioperative dexmedetomidine does not significantly reduce the risk of acute kidney injury after non-cardiac surgery based on randomized trial data, while increasing the risk of intra-operative bradycardia.
Hu et al. (2022) studied this question. Perioperative dexmedetomidine administration did not reduce the risk of post-operative acute kidney injury after non-cardiac surgery compared to placebo (OR 0.44, P = 0.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: